1. Home
  2. Knowledge
  3. Comparisons
  4. Semaglutide vs. tirzepatide
Comparison

Semaglutide vs. tirzepatide: what is the difference?

Both are among the most effective medicines for weight management. They differ in their mechanism and in their trial results.

Updated Nov 21, 20263 min readBeBetr editorial teamCreated with AI assistance

In short

  • Semaglutide acts on one receptor (GLP-1), tirzepatide on two (GIP and GLP-1).
  • In the head-to-head SURMOUNT-5 trial, people with obesity lost on average 20.2% of their weight on tirzepatide and 13.7% on semaglutide.
  • For semaglutide, the SELECT trial already shows fewer cardiovascular events in people without diabetes.
Semaglutide
GLP-1
Tirzepatide
GIP + GLP-1
Given
both weekly (pen)
Prescription
both required

The two medications at a glance

SemaglutideTirzepatide
MechanismGLP-1 receptor agonistdual GIP and GLP-1 receptor agonist
Products (EU)Ozempic, Wegovy, RybelsusMounjaro
Givenweekly by pen or daily as a tabletweekly by pen
Weight in the pivotal trial−14.9% after 68 weeks (STEP 1, 2.4 mg)up to −20.9% after 72 weeks (SURMOUNT-1, highest dose)
Head-to-head (SURMOUNT-5)−13.7% after 72 weeks−20.2% after 72 weeks
Most common side effectsnausea, diarrhoea, vomiting, constipationsimilar gastrointestinal profile

One receptor or two

Semaglutide mimics the gut hormone GLP-1. Tirzepatide additionally acts on a second receptor, that of the gut hormone GIP. Both are incretins that support insulin release after meals. Exactly how the extra GIP action contributes to the larger weight loss is still being researched.

What the trials show

The pivotal trials STEP 1 and SURMOUNT-1 can only be compared with caution, because participants, duration and doses differed. The head-to-head SURMOUNT-5 trial is more meaningful: 751 adults with obesity but without diabetes received the highest tolerated dose of either medicine for 72 weeks. Weight fell by 20.2% on average with tirzepatide and by 13.7% with semaglutide.

In type 2 diabetes, SURPASS-2 compared tirzepatide with semaglutide 1 mg: over 40 weeks, all tirzepatide doses lowered HbA1c more than semaglutide at that dose.

For semaglutide, the SELECT trial showed that major cardiovascular events were less frequent in people with heart disease and overweight. More on the semaglutide page.

Side effects

Both medications have a similar profile: nausea, diarrhoea, vomiting and constipation are most common, especially during the gradual dose increase (titration). The product information for both also includes warnings, for example about the gallbladder and pancreas.

Which one fits?

That depends on existing conditions, goals, tolerability, availability and reimbursement – and is a medical decision. Whatever the medication: enough protein, strength training and regular lab checks help you stay healthy along the way. The protein calculator shows a suitable range.

Protocol in the app

Doses, injection sites and supply at a glance

Document your prescribed therapy: reminders, injection-site rotation, vials and history – privately synced.

Frequently asked questions

Is Mounjaro stronger than Ozempic?

In the head-to-head SURMOUNT-5 trial, tirzepatide (Mounjaro) led to more weight loss in obesity than semaglutide. Ozempic itself is approved for type 2 diabetes; for weight management, the semaglutide product is called Wegovy.

Can you switch from semaglutide to tirzepatide?

Switching is a medical decision, including a new starting dose and increase. Never switch on your own.

Do both have the same side effects?

The profile is similar, mainly gastrointestinal symptoms. How strongly they occur varies from person to person.

Sources

  1. Aronne LJ et al.: Tirzepatide as compared with semaglutide for the treatment of obesity (SURMOUNT-5). N Engl J Med 2025
  2. Wilding JPH et al.: Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med 2021
  3. Jastreboff AM et al.: Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med 2022
  4. Frías JP et al.: Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2). N Engl J Med 2021
  5. Lincoff AM et al.: Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). N Engl J Med 2023
  6. EMA: Wegovy (semaglutide) – product information
  7. EMA: Mounjaro (tirzepatide) – product information

Written by the BeBetr editorial team with AI assistance; facts checked against the sources listed (as of Nov 21, 2026). This content is for information only and does not replace medical advice, diagnosis or treatment.

Keep reading